Did you mean?
Search Results - Showing 0 - 12 Of 33
_once-weekly-selinexor-carfilzomib-and-dexamethasone-xkdin-carfilzomib-non-refractory-multiple-myeloma-mm-patients.jpg "Prof Cristina Gasparetto speaks to ecancer about the efficacy of once weekly selinexor, carfilzomib, and dexamethasone (XKD)in carfilzomib non-refractory multiple myeloma (MM) patients. nnInitially, she explains the background of this study. Prof Gasparetto then talks about the methodology and key results of this study. nnIn patients with heavily pretreated MM, weekly XKd is highly active with an ORR of 78% and deep responses (≥VGPR 48%) with an overall PFS of 23 months. All AEs, including gra")
⏲ 4 min 69 sec ✓ 25-Jun-2021
_all-about-xpovio-selinexor.jpg "HealthTree University Myeloma")
⏲ 17 minutes 56 seconds 👁 913
_mechanism-of-action-of-selinexor-for-the-treatment-of-multiple-myeloma.jpg "Targeted Oncology")
⏲ 2 minutes 14 seconds 👁 246
_ash-2016-multiple-myeloma-highlights.jpg "Prof Marivi Mateos (University Hospital of Salamanca, Salamanca, Spain) chairs an expert discussion on the latest in Multiple Myeloma (MM) for ecancertv at ASH 2016 in San Diego.nnWith Prof Philippe Moreau (University Hospital of Nantes, Nantes, France), Prof Saad Usmani (Carolinas Healthcare System, Charlotte, USA) and Prof Heinz Ludwig (Wilhelminenspital, Center for Oncology and Hematology, Vienna, Austria).nnThe discussion started by looking at newly diagnosed multiple myeloma patients, with")
⏲ 9 min 93 sec ✓ 17-Mar-2017
_selinexor-a-clear-role-in-heavily-pre-treated-multiple-myeloma.jpg "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
⏲ 3 minutes 50 seconds 👁 190
_how-long-will-i-live-with-multiple-myeloma-and-is-there-a-cure.jpg "HealthTree University Myeloma")
⏲ 6 minutes 23 seconds 👁 45.1K
_expert-panel-discussion-on-the-use-of-novel-therapies-in-multiple-myeloma.jpg "World Myeloma Forum Expert Panel members Sagar Lonial, MD; Suzanne Lentzsch, MD, PhD; Ravi Vij, MD, MBA; and Ola Landgren, MD, PhD discuss data presented at ASH 2017 on the use of Novel Therapies in Multiple Myeloma.nnThe panel discusses four (4) abstracts presented at ASH using Novel Therapies including Venetoclax, GSK2857916, and Selinexor and their implication in the management of patients with Multiple Myeloma:nnAbstract 3131: Phase 1 Study of Venetoclax in Combination with Dexamethasone As")
⏲ 5 min 75 sec ✓ 23-Jan-2018
_medical-stories-multiple-myeloma-kenny39s-story.jpg "Medical Stories")
⏲ 14 minutes 22 seconds 👁 27.4K
_following-amp-understanding-your-free-light-chain-test-results.jpg "Myeloma Canada")
⏲ 1 hour 3 minutes 20 seconds 👁 14.5K
_multiple-myeloma-in-2023-what-patients-amp-caregivers-need-to-know-now-124-the-patient-story.jpg "The Patient Story")
⏲ 31 minutes 15 seconds 👁 16K
_multiple-myeloma-mechanism-of-action.jpg "CAST PHARMA")
⏲ 1 minute 17 seconds 👁 17.5K
_how-to-fight-against-multiple-myeloma-a-multiple-myeloma-survivor-story.jpg "Dana-Farber Cancer Institute")
⏲ 38 minutes 40 seconds 👁 23.4K
Related Searches
Search Videos
Recent Searches
_once-weekly-selinexor-carfilzomib-and-dexamethasone-xkdin-carfilzomib-non-refractory-multiple-myeloma-mm-patients.webp "Prof Cristina Gasparetto speaks to ecancer about the efficacy of once weekly selinexor, carfilzomib, and dexamethasone (XKD)in carfilzomib non-refractory multiple myeloma (MM) patients. nnInitially, she explains the background of this study. Prof Gasparetto then talks about the methodology and key results of this study. nnIn patients with heavily pretreated MM, weekly XKd is highly active with an ORR of 78% and deep responses (≥VGPR 48%) with an overall PFS of 23 months. All AEs, including gra")
_all-about-xpovio-selinexor.webp "HealthTree University Myeloma")
_mechanism-of-action-of-selinexor-for-the-treatment-of-multiple-myeloma.webp "Targeted Oncology")
_ash-2016-multiple-myeloma-highlights.webp "Prof Marivi Mateos (University Hospital of Salamanca, Salamanca, Spain) chairs an expert discussion on the latest in Multiple Myeloma (MM) for ecancertv at ASH 2016 in San Diego.nnWith Prof Philippe Moreau (University Hospital of Nantes, Nantes, France), Prof Saad Usmani (Carolinas Healthcare System, Charlotte, USA) and Prof Heinz Ludwig (Wilhelminenspital, Center for Oncology and Hematology, Vienna, Austria).nnThe discussion started by looking at newly diagnosed multiple myeloma patients, with")
_selinexor-a-clear-role-in-heavily-pre-treated-multiple-myeloma.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
_how-long-will-i-live-with-multiple-myeloma-and-is-there-a-cure.webp "HealthTree University Myeloma")
_expert-panel-discussion-on-the-use-of-novel-therapies-in-multiple-myeloma.webp "World Myeloma Forum Expert Panel members Sagar Lonial, MD; Suzanne Lentzsch, MD, PhD; Ravi Vij, MD, MBA; and Ola Landgren, MD, PhD discuss data presented at ASH 2017 on the use of Novel Therapies in Multiple Myeloma.nnThe panel discusses four (4) abstracts presented at ASH using Novel Therapies including Venetoclax, GSK2857916, and Selinexor and their implication in the management of patients with Multiple Myeloma:nnAbstract 3131: Phase 1 Study of Venetoclax in Combination with Dexamethasone As")
_medical-stories-multiple-myeloma-kenny39s-story.webp "Medical Stories")
_following-amp-understanding-your-free-light-chain-test-results.webp "Myeloma Canada")
_multiple-myeloma-in-2023-what-patients-amp-caregivers-need-to-know-now-124-the-patient-story.webp "The Patient Story")
_multiple-myeloma-mechanism-of-action.webp "CAST PHARMA")
_how-to-fight-against-multiple-myeloma-a-multiple-myeloma-survivor-story.webp "Dana-Farber Cancer Institute")
![[+]](/images/menu.gif){kind=small}